• Forum
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Oncopeptides

1.59 SEK+0.51 %10.7, 9.18
Less than 1K followers

ONCO

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Compare
+0.51 %
-7.07 %
+16.48 %
-63.13 %
-64.93 %
-44.14 %
-70.12 %
-96.45 %
-94.17 %

Oncopeptides is a biotechnology company developing drugs for difficult-to-treat hematological diseases. The company uses its PDC platform to develop peptide-linked drugs that selectively deliver cytotoxic agents into cancer cells. The company has drugs for commercialization, and has several drug candidates in development. Oncopeptides was founded in 2000 and is headquartered in Stockholm.

Read more
Market cap
628.51M SEK
Turnover
401.55K SEK
Revenue
71.12M
EBIT %
-315.87 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
All
Webcasts
Press releases
3rd party
ShowingAll content types

Forum discussions
Oncopeptides AB is a Swedish biotech company that, after a long development phase, has successfully developed and commercialized a drug called Pepaxti. This drug is intended for use in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have...
1/1/2026, 6:25 PM
by Hawkmountdiver
6
Q1 2026 Report is out Oncopeptides Oncopeptalks: Q1 report - Oncopeptides In the latest episode of Oncopeptalks, CEO Sofia Heigis and CFO Henrik Bergentoft comments on the Q1 report and other news presented during the week.
5/19/2026, 9:25 AM
by Hawkmountdiver
2
Read more on our forum
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
27.8
2026

Interim report Q2'26

5.11
2026

Interim report Q3'26

Regulatory press release30.06.2026, 17.30

Number of shares and votes in Oncopeptides

Oncopeptides
Press release17.06.2026, 13.45

First patient enrolled in Oncopeptides’ glioblastoma study

Oncopeptides
Press release12.06.2026, 12.59

Oncopeptides submits Type II variation application to EMA for Pepaxti label expansion into third line treatment

Oncopeptides

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Press release08.06.2026, 08.30

First patient enrolled in Oncopeptides’ real-world evidence study MARINA in Germany

Oncopeptides
Press release27.05.2026, 08.30

Oncopeptides to present clinical and translational data on Pepaxti at EHA 2026 in Stockholm

Oncopeptides
Press release26.05.2026, 08.00

Oncopeptides signs agreement with Salus for distribution and commercialization of Pepaxti in Central and Eastern Europe

Oncopeptides
Regulatory press release21.05.2026, 17.15

Bulletin from the Annual General Meeting in Oncopeptides

Oncopeptides
Press release20.05.2026, 13.30

Study confirms use of Pepaxti in a broader population, with strong data in the 50% of RRMM patients that suffer from reduced kidney function

Oncopeptides
Press release20.05.2026, 11.21

Redeye: Oncopeptides (Q1 Update): Strong Quarterly Growth and Decreased Costs

Oncopeptides
Press release19.05.2026, 16.36

Oncopeptides secures regulatory approval to start Window-of-Opportunity study in glioblastoma from Norwegian authorities

Oncopeptides
Press release18.05.2026, 12.14

Redeye: Oncopeptides (Q1 Update): Strong Quarterly Growth and Decreased Costs

Oncopeptides
Press release13.05.2026, 12.30

COMy: New clinical and real-world evidence for Pepaxti demonstrating strong data and expanded positioning

Oncopeptides
Oncopeptides, Audiocast, Q1'26
Webcast13.05.2026, 09.00

Oncopeptides, Audiocast, Q1'26

Oncopeptides
Regulatory press release13.05.2026, 08.00

Oncopeptides publishes Q1 report 2026

Oncopeptides
Oncopeptides, Audiocast, Press Conference, 2026
Webcast11.05.2026, 12.00

Oncopeptides, Audiocast, Press Conference, 2026

Oncopeptides
Regulatory press release11.05.2026, 08.15

Oncopeptides intends to submit type II variation to expand Pepaxti label to include third line treatment

Oncopeptides
Press release06.05.2026, 08.00

Invitation to presentation of the Q1 report 2026

Oncopeptides
Regulatory press release28.04.2026, 17.30

Oncopeptides publishes the 2025 Annual Report

Oncopeptides
Regulatory press release16.04.2026, 08.30

Annual General Meeting in Oncopeptides

Oncopeptides
Press release13.04.2026, 13.30

Preclinical data on novel NK-Cell engager to be presented at the AACR Annual Meeting 2026

Oncopeptides